

# Lorena Rami Gonzalez

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5942126/lorena-rami-gonzalez-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61  
papers

2,980  
citations

23  
h-index

54  
g-index

71  
ext. papers

3,736  
ext. citations

4.3  
avg, IF

4.27  
L-index

#	Paper	IF	Citations
61	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , <b>2022</b> ,	17.2	9
60	Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid- $\beta$ positivity. <i>International Journal of Geriatric Psychiatry</i> , <b>2021</b> , 36, 1037-1049	3.9	2
59	Accelerated long-term forgetting over three months in asymptomatic APOE e4 carriers. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 477-484	5.3	5
58	Distinct neuropsychological presentation and progression between early- and late-onset Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e036809	1.2	
57	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e036954	1.2	1
56	Accelerated long-term forgetting over six months in cognitively normal APOE e4 carriers. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, e041928	1.2	
55	Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 262-272	1.2	29
54	Sex Differences of Longitudinal Brain Changes in Cognitively Unimpaired Adults. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 76, 1413-1422	4.3	1
53	Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid- $\beta$ positivity. <i>Cortex</i> , <b>2019</b> , 121, 117-124	3.8	3
52	Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 8	9	19
51	Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 70, 211-225	4.3	6
50	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 817-827	1.2	26
49	Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 33	9	22
48	Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease. <i>NeuroImage: Clinical</i> , <b>2019</b> , 22, 101777	5.3	17
47	CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. <i>NeuroImage: Clinical</i> , <b>2019</b> , 23, 101801	5.3	17
46	Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment. <i>NeuroImage: Clinical</i> , <b>2019</b> , 23, 101927	5.3	18
45	Associations Between the Subjective Cognitive Decline-Questionnaire's Scores, Gray Matter Volume, and Amyloid- $\beta$ Levels. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 72, 1287-1302	4.3	5

44	IC-02-05: GENDER DIFFERENCES IN THE ASSOCIATION BETWEEN LONGITUDINAL BRAIN CHANGES AND BASELINE LEVELS OF CSF ALZHEIMER'S DISEASE AND GLIAL BIOMARKERS IN HEALTHY ELDERLS <b>2019</b> , 15, P4-P4		
43	Physical activity is associated with better global cognition and frontal function in overweight/obese older adults with metabolic syndrome. <i>European Review of Aging and Physical Activity</i> , <b>2019</b> , 16, 23	6.5	6
42	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. <i>Molecular and Cellular Proteomics</i> , <b>2019</b> , 18, 546-560	7.6	66
41	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 185-193	1.2	19
40	Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. <i>NeuroImage: Clinical</i> , <b>2018</b> , 19, 190-201	5.3	15
39	Wishes and preferences for an online lifestyle program for brain health-A mixed methods study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2018</b> , 4, 141-149	6	7
38	The Rationale Behind the New Alzheimer's Disease Conceptualization: Lessons Learned During the Last Decades. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 62, 1067-1077	4.3	15
37	Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid- $\beta$ and Tau. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 61, 1575-1587	4.3	20
36	Executive and Language Subjective Cognitive Decline Complaints Discriminate Preclinical Alzheimer's Disease from Normal Aging. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 61, 689-703	4.3	19
35	P2-262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM <b>2018</b> , 14, P777-P777		
34	Computer-assisted prediction of clinical progression in the earliest stages of AD. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 726-736	5.2	8
33	Subtle visuomotor difficulties in preclinical Alzheimer's disease. <i>Journal of Neuropsychology</i> , <b>2017</b> , 11, 56-73	2.6	8
32	The $\beta$ genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 6, 50-59	5.2	29
31	Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimer's Disease Stage 1. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 58, 855-870	4.3	12
30	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. <i>Molecular Neurobiology</i> , <b>2017</b> , 54, 6647-6654	6.2	29
29	Implementation of subjective cognitive decline criteria in research studies. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 296-311	1.2	245
28	[P2B55]: CSF STREM2, BUT NOT YKL-40, IS ASSOCIATED WITH LONGITUDINAL MORPHOLOGICAL BRAIN CHANGES IN PRECLINICAL ALZHEIMER'S DISEASE <b>2017</b> , 13, P758-P758		
27	[P3B66]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE <b>2017</b> , 13, P1195-P1196		

26	[P4014]: TOWARD A FUNCTIONAL NEUROMARKER FOR PRECLINICAL AD: EIGENVECTOR CENTRALITY REVEALS PRECLINICAL DIFFERENCES OF FUNCTIONAL INFORMATION FLOW IN THE HIPPOCAMPUS, PRECUNEUS, CEREBELLUM AND INFERIOR PARIETAL LOBULE <b>2017</b> , 13, P1348-P1349		
25	[TD-P-020]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE <b>2017</b> , 13, P166-P167		
24	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 1259-1272	1.2	67
23	P2-335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples <b>2016</b> , 12, P770-P771		
22	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. <i>Neurobiology of Aging</i> , <b>2016</b> , 38, 47-55	5.6	42
21	Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimer's Disease. <i>Molecular Neurobiology</i> , <b>2016</b> , 53, 5902-5911	6.2	9
20	IC-02-05: Cerebrospinal Fluid Strem2 Levels are Associated with Gray Matter Volume Increases and Reduced Diffusivity in Early Alzheimer's Disease <b>2016</b> , 12, P8-P8		
19	Initial phase of adaptation of Memory Alteration Test (M@T) in a Portuguese sample. <i>Archives of Gerontology and Geriatrics</i> , <b>2015</b> , 61, 103-8	4	7
18	IC-P-048: Longitudinal changes in gray matter volume in preclinical Alzheimer's disease <b>2015</b> , 11, P38-P39		
17	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 48 Suppl 1, S63-86	4.3	253
16	Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 48 Suppl 1, S87-98	4.3	39
15	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 48 Suppl 1, S171-91	4.3	29
14	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2014</b> , 10, 844-52	1.2	1219
13	Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 42, 901-8	4.3	79
12	The Subjective Cognitive Decline Questionnaire (SCD-Q): a validation study. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 41, 453-66	4.3	76
11	White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid $\beta$ protein 42 levels. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 2671-2680	5.6	56
10	Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 40, 919-27	4.3	27
9	Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , <b>2014</b> , 4, 297-304	2.5	63

8	Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. <i>International Journal of Geriatric Psychiatry</i> , <b>2012</b> , 27, 127-34	3.9	33
7	Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 31, 517-26	4.3	39
6	Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 564-573	13.4	78
5	Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 23, 319-26	4.3	56
4	Voxel based morphometry features and follow-up of amnesic patients at high risk for Alzheimer's disease conversion. <i>International Journal of Geriatric Psychiatry</i> , <b>2009</b> , 24, 875-84	3.9	15
3	Cognitive functions after only one ECT session: a controlled study. <i>Psychiatry Research</i> , <b>2008</b> , 158, 389-94	4.9	11
2	Normative data for the Boston Naming Test and the Pyramids and Palm Trees Test in the elderly Spanish population. <i>Journal of Clinical and Experimental Neuropsychology</i> , <b>2008</b> , 30, 1-6	2.1	34
1	Cognitive status of psychiatric patients under maintenance electroconvulsive therapy: a one-year longitudinal study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , <b>2004</b> , 16, 465-71	2.7	21